Emerald Bioscience Announces Financing Update and Board Re-organization
23. Dezember 2019 08:30 ET
|
Emerald Bioscience, Inc.
Emerald Health Sciences To Exercise 40.8 Million Warrants, Reducing Outstanding Debt, As Company Changes Name to Embi Pharmaceuticals Punit Dhillon Assumes Board Chairmanship as Dr. Avtar Dhillon...
Emerald Bioscience Reports its Proprietary Analog of Cannabidiol, Cannabidiol-Valine-Hemisuccinate (CBDVHS), Exhibits Greater Potency and Antifibrotic Activity than Cannabidiol (CBD) in Biomarker Studies in Human Ocular Donor Tissues
09. Dezember 2019 08:30 ET
|
Emerald Bioscience, Inc.
CBDVHS Also Displayed Superior Anti-Inflammatory Activity When Compared to CBD Indicating Potential Use in Diseases of the Retina Unlike CBD, CBDVHS was not Associated with Biomarkers Related to...
Emerald Bioscience to Present at Cowen 2nd Annual Boston Cannabis Conference
04. November 2019 08:30 ET
|
Emerald Bioscience, Inc.
LONG BEACH, CA, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications,...
Emerald Bioscience’s NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model
15. Oktober 2019 08:35 ET
|
Emerald Bioscience, Inc.
LONG BEACH, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global...
Glauconix Presents Data Validating Impact of Emerald Bioscience’s Prodrug on the Ocular Endocannabinoid System in Glaucoma
15. Oktober 2019 08:30 ET
|
Emerald Bioscience, Inc.
Study Points to Unique Link Between the Endocannabinoid System and the Inflammatory Cascade in the Eye LONG BEACH, CA, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc....
Emerald Bioscience to Present at the 9th Annual LD Micro Invitational
03. Juni 2019 08:00 ET
|
Emerald Bioscience, Inc.
LONG BEACH, CA, June 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...
Emerald Bioscience Secures “All Fields” Licenses for Cannabinoid Derivatives Developed by University of Mississippi
29. Mai 2019 08:00 ET
|
Emerald Bioscience, Inc.
Licenses Permit Emerald to Develop THC-Prodrug and CBD-Analog for Any Therapeutic Indication by Any Route of Administration for Human and Veterinary Use LONG BEACH, CA, May 29, 2019 (GLOBE...
Emerald Bioscience to Participate at the CannaStocks 2019 Q1 Investor Conference
13. Mai 2019 08:00 ET
|
Emerald Bioscience, Inc.
LONG BEACH, CA , May 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical...
Emerald Bioscience to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
08. April 2019 08:30 ET
|
Emerald Bioscience, Inc.
LONG BEACH, CA, April 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based...
Emerald Bioscience, Inc. Announces DEA Decision that its Proprietary Cannabidiol Analog is not a Regulated Chemical or Controlled Substance Under Controlled Substances Act
01. April 2019 07:30 ET
|
Emerald Bioscience, Inc.
LONG BEACH, CA, April 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based...